BOTA Insider Trading Activity and SEC Form 4 Filings
BOTA insider trading summary
No open-market insider purchases or sales of Biota Pharmaceuticals, Inc. (BOTA) have been reported on SEC Form 4 in the past 12 months.
Latest BOTA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 9, 2016 | Mark P Colonnese | Chief Financial Officer | Buy | $419 (300 @ $1.40) |
| Feb 9, 2016 | Mark P Colonnese | Chief Financial Officer | Buy | $9K (6,700 @ $1.41) |
| Sep 25, 2015 | Joseph M Patti | CEO | Buy | $5K (2,500 @ $1.85) |
| Sep 25, 2015 | Joseph M Patti | CEO | Buy | $5K (2,500 @ $1.89) |
| Jun 22, 2015 | Anne Vanlent | Director | Buy | $77K (35,000 @ $2.20) |
| Jun 9, 2015 | James Fox | Director | Buy | $139K (70,000 @ $1.99) |
| Mar 27, 2015 | Joseph M Patti | CEO | Buy | $23K (10,000 @ $2.27) |
| Mar 27, 2015 | Joseph M Patti | CEO | Buy | $23K (10,000 @ $2.30) |
| Jun 30, 2014 | Joseph M Patti | EVP, Corporate Dev & Strategy | Buy | $29K (10,000 @ $2.86) |
| Jun 27, 2014 | Joseph M Patti | EVP, Corporate Dev & Strategy | Buy | $12K (4,200 @ $2.81) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.